Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Details 1)

Discontinued Operations (Details 1) - USD ($)	3 Months Ended	6 Months Ended
Discontinued Operations (Details 1) - USD ($)	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Discontinued Operations
Revenues		$ 0	$ 3,000
Operating Expenses		0	(25,000)
Net income	$ 404,111	$ 0	$ (22,000)

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details